Claims
- 1. A method for the treatment of cellulitis which comprises massaging the part of the body to be treated with a therapeutically effective amount of a composition containing in a suitable vehicle:
- (1) 0.1 to 1.5% by weight of a thioether selected from the group consisting of: S-carboxymethylcysteine, S-carboxymethylhomocysteine, thiolane-3,4-diol, thiolane-3,4-diol S-oxide, thiolane-3,4-diol S-dioxide and the malate, salicylate, nicotinate, tartrate or 5-amino-3-thiahexanedioate of 2-benzylthioethylamine, and
- (2) 0.1 to 2% by weight of a xanthine derivative having the formula: ##STR2## in which each of R.sub.1 and R.sub.3 independently represents a hydrogen atom, a linear or branched alkyl radical having 1 to 5 carbon atoms, an allyl radical, a propynyl radical or a cyclohexyl radical with the proviso that R.sub.1 and R.sub.3 do not simultaneously represent a hydrogen atom and R.sub.2 represents hydrogen, a methyl, ethyl, hydroxymethyl or hydroxyethyl radical.
- 2. The process of claim 1 in which said treatment is carried out once a day for 2 to 8 weeks.
- 3. The process of claim 1 in which said xanthine derivative is selected from the group consisting of theophylline, theobromine, caffeine, 3-butyl-1-methylxanthine, 3-isobutyl-1-methylxanthine, 1,3,7-triethylxanthine, 3-cyclohexyl-1-ethylxanthine, 3-ethyl-1-propynylxanthine and 3-ethyl-1-pentylxanthine.
- 4. A method for the treatment of cellulitis which comprises treating the skin, using the transcutaneous electrophoresis technique, with a therapeutically effective amount of an aqueous solution containing:
- (1) 0.1 to 1.5% by weight of a thioether selected from the group consisting of: S-carboxymethylcysteine, S-carboxymethylhomocysteine, thiolane-3,4-diol, thiolane-3,4-diol S-oxide, thiolane-3,4-diol S-dioxide and the malate, salicylate, nicotinate, tartrate or 5-amino-3-thiahexanedioate of 2-benzylthioethylamine, and
- (2) 0.1 to 2% by weight of a xanthine derivative having the formula: ##STR3## in which each of R.sub.1 and R.sub.3 independently represents a hydrogen atom, a linear or branched alkyl radical having 1 to 5 carbon atoms, an allyl radical, a propynyl radical or a cyclohexyl radical with the proviso that R.sub.1 and R.sub.3 do not simultaneously represent a hydrogen atom and R.sub.2 represents hydrogen, a methyl, ethyl, hydroxymethyl or hydroxyethyl radical.
- 5. The process of claim 4 in which said treatment is carried out for 4 to 8 weeks at a rate of three ionisations per week.
- 6. The process of claim 4 in which said xanthine derivative is selected from the group consisting of theophylline, theobromine, caffeine, 3-butyl-1-methylxanthine, 3-isobutyl-1-methylxanthine, 1,3,7-triethylxanthine, 3-cyclohexyl-1-ethylxanthine, 3-ethyl-1-propynylxanthine and 3-ethyl-1-pentylxanthine.
Priority Claims (1)
Number |
Date |
Country |
Kind |
76148 |
Nov 1976 |
LUX |
|
Parent Case Info
This application is a division of Ser. No. 849,128, filed Nov. 7, 1978 now abandoned.
US Referenced Citations (11)
Non-Patent Literature Citations (2)
Entry |
Chem. Abst. 71, 120114(c) (1969)-Cuthbent et al. |
Gazette Medicale de France-Paris, 79 (33) (1972)-pp. 5906-5908-Sors. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
849128 |
Nov 1978 |
|